Member Info for RorkesDrift

colorectal cancer

http://etheses.whiterose.ac.uk/23772/

This one attaches an affimer to an electrode. When the target protein binds you get a change in impedance (think v=ir) which you can measure. Biomarkers and bed side tests are the future. Avacta bringing in house because struggling to get third parties to adopt.

2017

This study indicates that Affimer-MAb CLIA can be used to generate a sensitive immunodiagnostic kit, which offers the potential for a highly specific clinically-relevant detection system.

https://www.nature.com/articles/s41598-017-10083-w

http://eprints.whiterose.ac.uk/127708/1/Zhurauski%20_Tomlinson%20-%20manuscript%20revised.pdf

Apologies - post crossed.

AstraZeneca has licensed coronavirus-neutralising antibodies from Vanderbilt University, US, and plans to advance a pair of these mAbs into clinical development as a potential combination therapy for the prevention and treatment of COVID-19. This agreement builds on the Company’s collaboration agreement with Vanderbilt, announced in April 2020.

Following rapid mobilisation of its global research efforts, AstraZeneca has evaluated the ability of more than 1,500 mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect healthy cells in a laboratory setting. Based on these pre-clinical results, the Company has signed an exclusive license to six candidate antibodies currently in Vanderbilt’s portfolio that target the SARS-CoV-2 virus. Two mAbs from these six will progress into clinical evaluation as a combination approach within the next two months.

AstraZeneca has also signed an interagency agreement with the Defense Advanced Research Projects Agency, part of the US Department of Defense, and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to support the company’s efforts to develop a mAb treatment against SARS-CoV-2, including a Phase I clinical trial and the manufacturing of the investigational product for testing in Phase I.

AstraZeneca has licensed coronavirus-neutralising antibodies from Vanderbilt University, US, and plans to advance a pair of these mAbs into clinical development as a potential combination therapy for the prevention and treatment of COVID-19. This agreement builds on the Company’s collaboration agreement with Vanderbilt, announced in April 2020.

Following rapid mobilisation of its global research efforts, AstraZeneca has evaluated the ability of more than 1,500 mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect healthy cells in a laboratory setting. Based on these pre-clinical results, the Company has signed an exclusive license to six candidate antibodies currently in Vanderbilt’s portfolio that target the SARS-CoV-2 virus. Two mAbs from these six will progress into clinical evaluation as a combination approach within the next two months.

AstraZeneca has also signed an interagency agreement with the Defense Advanced Research Projects Agency, part of the US Department of Defense, and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to support the company’s efforts to develop a mAb treatment against SARS-CoV-2, including a Phase I clinical trial and the manufacturing of the investigational product for testing in Phase I.

I watched last night. If only the CDC were that good. Amazing how prescient that was.

The bugle player was sent to sick bay for a natal swab

Enjoy the telly

The whole future of medicine is entering new territory. Monoclonal antibodies were amazing when they first appeared and now there are shed loads in development. They are now a bit boring when you look at stuff like CAR-T cells which feels like something out of Star Trek to me. Add in gene therapy and stem cells and pills in boxes is very last century. Really exciting time to be an invested.

I think affirmers is a step on from antibodies. Looking back the company seemed only to have switched on to what they have recently - hope they make the most of what they have in their hands or at least focus on what will make the biggest difference. I have got a feeling the next RNS which will arrive on a Tuesday will be about something non- Covid.

Nebulized budesonide - I've looked but already available. Amazing cheap drug already here makes such a difference. I am crystal calling but I bet asprin will show a difference along with clopidogrel

That I would like to see but cannot find it.

Myself, Rich Ken, Pl75 and Orphidian are currently working on our version of this for next years annual meeting. Language is Zulu

https://youtu.be/N67GdbRa5NY

BAMS gives them two bites of the cherry. It also provides proof of concept for this approach.

Did I mention D-dimers?

I tried to start one - didn't get very far but I have to say its a genius idea

The numbers were straight out of the 2019 report which are the latest I am aware of. Not saying they are not affected cause they are pre-covid but they are fairly small

Given we habe a brace of vets and I cannot spell vetniry what is your view of them as a company and the opportunity - they state they have the best offer but I don't know whether this is necessary or true. Perhaps they will sell off - economy of scale seems to matter in vet land?

Avacta Animal Health
increased to £2.18 million (2018: £1.57 million) as the
division focused on its core pet/equine allergy tests
together with expanding its overseas products/services

FM - wow

Insert big yellow thumb

I mean....

Vets round here were closed for anything routine for pets - even the farrier was a bit wary. That said you could lose all there animal revenue and combared to what they are aiming at you wouldn't notice.

D-Dimer is a degradation product of cross-linked fibrin that is formed immediately after thrombin-generated fibrin clots are
degraded by plasmin and reflects a global activation of blood coagulation and fibrinolysis. As D-Dimer levels rise during an acute event of VTE, testing for D-Dimer was explored as a tool for the diagnosis of VTE and has been integrated into diagnostic algorithms in the management of patients with suspected VTE.3–5 Being the best-recognized biomarker for the initial assessment of suspected VTE, a negative value of D-Dimer may safely rule out both DVT and PE with a high sensitivity of up to 95% and a negative predictive value of nearly 100%

1. D-dimer affimer. Biomarker of clot formation.

The chemotherapy is more run of the mill. The SP before Covid recognised risk : reward. Its a great concept and the animal work is emcpuraging. In clinic early next year for phase 1.

I've read the animal work but one question I would have if I was a clinician is the pro-dox converts to dox in tumour cells. Presumably that can then elevate systemic levels. But by how much - animal survival at 60 days suggests they have a solution to the toxicity of chemo.

2. Out of date. (Insert winky emoji)

4. If we look at other diagnostic projects point well made. However, recently brought in house and DW appointed

6. Both techs are licensed from others. Suggests expertise located outside of company

3 and 6 for me would be significant. Both in terms of control but also lost margin.

If volumes are as big as we think and covid here for as long as people fear then a bit of vertical integration would improve situation. On the upside they have £10M put aside so that could be used. I'm not a fan of Medusa19 but I didn't know detailsvand I think they mentioned profit share

Oh come on. There must be a clever acronym for your approach - PESTLE?